- Home
- FTHM vs BYSI Comparison
FTHM vs BYSI Comparison
Compare FTHM & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHM | BYSI |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 31.4M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | FTHM | BYSI |
|---|---|---|
| Price | $0.58 | $0.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | 86.5K | ★ 2.0M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $420,477,000.00 | N/A |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.45 | N/A |
| 52 Week Low | $0.40 | $0.57 |
| 52 Week High | $3.37 | $2.44 |
Technical Indicators
Market Signals| Indicator | FTHM | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 34.36 | 48.14 |
| Support Level | $0.57 | $0.67 |
| Resistance Level | $0.71 | $1.25 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 13.33 | 86.45 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, and Software as a Service (SaaS) offerings to brokerages and agents by leveraging intelliAgent , proprietary cloud-based software. The Company's three operating and reportable segments: Real Estate Brokerage, Mortgage, and Title. The majority of revenue is from Real Estate Brokerage, which provides real estate brokerage services.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.